SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 3 filers reported holding SAGE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $619 | +15.1% | 30,071 | +113.0% | 0.01% | -25.0% |
| Q4 2022 | $538 | -100.0% | 14,116 | -79.6% | 0.01% | -77.1% |
| Q3 2022 | $2,711,000 | -41.3% | 69,233 | -51.6% | 0.04% | -38.6% |
| Q2 2022 | $4,617,000 | -18.4% | 142,955 | -16.4% | 0.06% | -20.8% |
| Q1 2022 | $5,657,000 | +144.9% | 170,910 | +227.8% | 0.07% | +132.3% |
| Q3 2021 | $2,310,000 | +33.0% | 52,134 | +70.5% | 0.03% | +63.2% |
| Q2 2021 | $1,737,000 | +460.3% | 30,580 | +637.4% | 0.02% | +280.0% |
| Q1 2021 | $310,000 | +49.8% | 4,147 | +73.2% | 0.01% | +150.0% |
| Q4 2020 | $207,000 | -85.5% | 2,395 | -89.7% | 0.00% | -92.9% |
| Q3 2020 | $1,425,000 | -9.3% | 23,310 | -38.3% | 0.03% | -31.7% |
| Q2 2020 | $1,571,000 | +152.2% | 37,786 | +1010.7% | 0.04% | +64.0% |
| Q2 2019 | $623,000 | – | 3,402 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 312,000 | $29,886,000 | 5.11% |
| DAFNA Capital Management LLC | 104,306 | $9,991,000 | 4.97% |
| Palo Alto Investors LP | 850,977 | $81,515,000 | 4.34% |
| BB BIOTECH AG | 1,375,229 | $131,733,000 | 4.22% |
| Eventide Asset Management | 936,000 | $89,659,000 | 3.97% |
| TRV GP II, LLC | 37,362 | $3,579,000 | 3.56% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 146,179 | $14,002,000 | 2.11% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 111,908 | $10,720,000 | 2.06% |
| OAK RIDGE INVESTMENTS LLC | 231,483 | $22,174,000 | 1.60% |
| Rhenman & Partners Asset Management AB | 137,339 | $13,156,000 | 1.50% |